FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027698934> ?p ?o ?g. }

• W2027698934 endingPage "548" @default.
• W2027698934 startingPage "536" @default.
• W2027698934 abstract "2- [18F]-fluoro-2-deoxy-d-glucose (FDG) is the radiopharmaceutical most frequently used for clinical positron emission tomography (PET). However, FDG cannot be used for many oncological, cardiological, or neurological conditions, either because the abnormal tissue does not concentrate it, or because the tissues under investigation demonstrate high physiological glucose uptake. Consequently, alternative PET tracers have been produced and introduced into clinical practice. The most important compounds in routine practice are 11C-choline and 18F-choline, mainly for the evaluation of prostate cancer; 1C-methionine for brain tumours; 118F-DOPA (18F- deoxiphenilalanine) for neuroendocrine tumours and movement disorders; 68Ga-DOTANOC (tetraazacyclododecanetetraacetic acid-[1-Nal3]-octreotide) and other somatostatin analogues for neuroendocrine tumours; 11C-acetate for prostate cancer and hepatic masses and 18F-FLT (3ٰ-deoxy-3ٰ-fluorothymidine) for a number of malignant tumours. Another impetus for the development of new tracers is to enable the investigation of biological processes in tumours other than glucose metabolism. This is especially important in the field of response assessment, where there are new agents that are targeted more specifically at angiogenesis, hypoxia, apoptosis and other processes. 2- [18F]-fluoro-2-deoxy-d-glucose (FDG) is the radiopharmaceutical most frequently used for clinical positron emission tomography (PET). However, FDG cannot be used for many oncological, cardiological, or neurological conditions, either because the abnormal tissue does not concentrate it, or because the tissues under investigation demonstrate high physiological glucose uptake. Consequently, alternative PET tracers have been produced and introduced into clinical practice. The most important compounds in routine practice are 11C-choline and 18F-choline, mainly for the evaluation of prostate cancer; 1C-methionine for brain tumours; 118F-DOPA (18F- deoxiphenilalanine) for neuroendocrine tumours and movement disorders; 68Ga-DOTANOC (tetraazacyclododecanetetraacetic acid-[1-Nal3]-octreotide) and other somatostatin analogues for neuroendocrine tumours; 11C-acetate for prostate cancer and hepatic masses and 18F-FLT (3ٰ-deoxy-3ٰ-fluorothymidine) for a number of malignant tumours. Another impetus for the development of new tracers is to enable the investigation of biological processes in tumours other than glucose metabolism. This is especially important in the field of response assessment, where there are new agents that are targeted more specifically at angiogenesis, hypoxia, apoptosis and other processes." @default.
• W2027698934 created "2016-06-24" @default.
• W2027698934 creator A5044657023 @default.
• W2027698934 creator A5060396380 @default.
• W2027698934 creator A5061879497 @default.
• W2027698934 creator A5063023121 @default.
• W2027698934 date "2010-07-01" @default.
• W2027698934 modified "2023-10-01" @default.
• W2027698934 title "Non FDG PET" @default.
• W2027698934 cites W1517190736 @default.
• W2027698934 cites W1965100670 @default.
• W2027698934 cites W1966464074 @default.
• W2027698934 cites W1973434317 @default.
• W2027698934 cites W1974352824 @default.
• W2027698934 cites W1975839853 @default.
• W2027698934 cites W1990715071 @default.
• W2027698934 cites W1990833800 @default.
• W2027698934 cites W1995099513 @default.
• W2027698934 cites W1997677667 @default.
• W2027698934 cites W1998087365 @default.
• W2027698934 cites W2000799481 @default.
• W2027698934 cites W2003943670 @default.
• W2027698934 cites W2015914446 @default.
• W2027698934 cites W2017454453 @default.
• W2027698934 cites W2020940298 @default.
• W2027698934 cites W2027329432 @default.
• W2027698934 cites W2029070398 @default.
• W2027698934 cites W2030040160 @default.
• W2027698934 cites W2030911024 @default.
• W2027698934 cites W2031849543 @default.
• W2027698934 cites W2033990051 @default.
• W2027698934 cites W2034066878 @default.
• W2027698934 cites W2035004989 @default.
• W2027698934 cites W2040659746 @default.
• W2027698934 cites W2043037767 @default.
• W2027698934 cites W2044196464 @default.
• W2027698934 cites W2049609118 @default.
• W2027698934 cites W2049726712 @default.
• W2027698934 cites W2050278505 @default.
• W2027698934 cites W2051771185 @default.
• W2027698934 cites W2052798244 @default.
• W2027698934 cites W2055224424 @default.
• W2027698934 cites W2056032942 @default.
• W2027698934 cites W2058610012 @default.
• W2027698934 cites W2059777719 @default.
• W2027698934 cites W2062516667 @default.
• W2027698934 cites W2067777670 @default.
• W2027698934 cites W2069319621 @default.
• W2027698934 cites W2073835458 @default.
• W2027698934 cites W2077640666 @default.
• W2027698934 cites W2079477817 @default.
• W2027698934 cites W2080164726 @default.
• W2027698934 cites W2081974094 @default.
• W2027698934 cites W2082298563 @default.
• W2027698934 cites W2087157490 @default.
• W2027698934 cites W2088147866 @default.
• W2027698934 cites W2089963766 @default.
• W2027698934 cites W2092860849 @default.
• W2027698934 cites W2096817071 @default.
• W2027698934 cites W2099479806 @default.
• W2027698934 cites W2101873804 @default.
• W2027698934 cites W2105315565 @default.
• W2027698934 cites W2107218263 @default.
• W2027698934 cites W2108261951 @default.
• W2027698934 cites W2116541516 @default.
• W2027698934 cites W2128006663 @default.
• W2027698934 cites W2137604142 @default.
• W2027698934 cites W2140475100 @default.
• W2027698934 cites W2140572440 @default.
• W2027698934 cites W2140866432 @default.
• W2027698934 cites W2141678579 @default.
• W2027698934 cites W2143731704 @default.
• W2027698934 cites W2143747410 @default.
• W2027698934 cites W2147136484 @default.
• W2027698934 cites W2149168238 @default.
• W2027698934 cites W2157524996 @default.
• W2027698934 cites W2159511117 @default.
• W2027698934 cites W2160771508 @default.
• W2027698934 cites W2162508878 @default.
• W2027698934 cites W2167932663 @default.
• W2027698934 cites W2168397357 @default.
• W2027698934 cites W2168524811 @default.
• W2027698934 cites W2168539551 @default.
• W2027698934 cites W2188410146 @default.
• W2027698934 cites W4253513090 @default.
• W2027698934 cites W74399661 @default.
• W2027698934 doi "https://doi.org/10.1016/j.crad.2010.03.012" @default.
• W2027698934 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20541653" @default.
• W2027698934 hasPublicationYear "2010" @default.
• W2027698934 type Work @default.
• W2027698934 sameAs 2027698934 @default.
• W2027698934 citedByCount "49" @default.
• W2027698934 countsByYear W20276989342012 @default.
• W2027698934 countsByYear W20276989342013 @default.
• W2027698934 countsByYear W20276989342014 @default.
• W2027698934 countsByYear W20276989342015 @default.
• W2027698934 countsByYear W20276989342016 @default.
• W2027698934 countsByYear W20276989342017 @default.

• next